Ghent-based antibody developer argenx has announced that Staten Biotech has exercised its exclusive option to license ARGX-116, an anti-ApoC3 SIMPLE AntibodyTM with therapeutic potential in dyslipidemia. This collaboration is the latest to stem from the argenx Innovative Access Program. 

In a press release stating strong annual results for the cancer diagnostic producer, Biocartis also announced a change in its top management position. Its current CEO, Rudi Pauwels, has expressed his preference to focus on the longer term strategy of Biocartis, including a pathway towards a Next-Generation Sequencing based product offering. Pauwels will act as chairman of a new strategy committee of the Board. Hilde Windels, currently Deputy CEO, will assume the role of CEO until a successor is on board.

argenx, the llama antibodies developer looking to treat severe autoimmune diseases and cancer, announced today that it has confidentially submitted a draft registration statement on Form F-1 to the U.S. Securities and Exchange Commission relating to the proposed registered public offering of its ordinary shares in the United States.

With the purpose of supporting customers throughout their entire biological drug development process, GMP specialist Anacura and the R&D-focused RIC have initiated a collaboration under the moniker ‘anaRIC biologics’.